Skip to main content
OpenTrials
Completed

NCT Number: NCT03015038

Study of the Immune Response in Colon Adenocarcinoma

Duration of each part of the study per patient:

* Screening: From 1 to 4 weeks * Sampling period (blood and tissue): 1 day * Follow-up by patient: 60 months * Total study duration by patient: 84 months * Total inclusion duration: 24 months * Total Follow-up duration: 60 months * Total study duration: 84 months

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colon Adenocarcinoma Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Saint Louis

Paris, 75000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 or more.
  • Affiliation to a social security scheme
  • Diagnosis of a colon adenocarcinoma.
  • Patient have signed and dated consent of the study before undertaking procedures related to the study.

Exclusion criteria

  • Patients under guardianship / curatorship
  • Following Situations
  • Persons unable to understand, read and / or sign an informed consent
  • Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study
  • Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year.
  • No affiliation to a social security scheme, a universal medical coverage or any similar plan.
  • Pregnant or lactating women.
  • Patients with HIV seropositivity.
  • Rectal tumor location.

Treatment and study plan

Primary outcomes

  1. Immune cells trafficking

    Time frame: Day 0

    Frequency of T cells in the blood and tissue (Flow cytometry method with a panel of Ab).

Secondary outcomes

  1. Infiltration of leucocytes in tumor tissue

    Time frame: Day 0

    Histochemical method with a panel of Ab.

  2. Safety (Number of adverse events, ECOG status)

    Time frame: After Day 0 until the end of the study (Month 3, Month 6, Month 9, Month 12, Month 15, Month 18,Month 21, Month 24, Month 30, Month 36, Month 42, Month 48, Month 54 and Month 60)

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Collaborators

  • Innate Pharma

Registry information

Official study title

Etude de la réponse Immunitaire Dans l'adénocarcinome Colique

Acronym: IMCO

Important dates

Study start
2017
Primary completion
2024
Study completion
2024
First posted
Jan 9, 2017
Registry last updated
Dec 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.